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Clinical trials have been fundamental in fostering the
development of novel treatments in medicine and for
understanding disease mechanisms. One important issue
in this field is how they continue to change over time. For
example, a recent study analyzing clinical trials in psychia-
try over the past 60 years showed substantial changes in the
use of statistical methods in the reporting of abstracts and
results, as well as increased use in recent trials of informed
consent, washout periods, the intention-to-treat approach
and parametric tests.1
Many of these changes have been shaped by historical
events. For example, the development of ethical guidelines
has been marked by three milestones: the Nuremberg Code2
made voluntary consent mandatory for clinical research; the
Declaration of Helsinki3 codified the ethical principles for
human experimental research and the infamous Tuskegee
Syphilis Study2 led to the Belmont Report, which increased
protection for human research subjects and defined
informed consent in different research settings.
Another important historical event that has shaped
clinical research is the issue of adverse effects associated
with novel interventions. One of the landmark examples is
the use of thalidomide, which resulted in unexpected harm
to the fetus. Here, the development of study phases (phases
I, II, III and IV) and additional pre-clinical studies has
greatly increased the safety of new drugs and devices.
Regulatory changes have also been important in increas-
ing the safety of clinical trials. A heated debate is currently
taking place on the use of placebos and the further
development of non-inferiority trials. At the same time,
some scientists claim that ethics committees are becoming
overly bureaucratic and not fulfilling their mission well.4
Options for balancing the prevention of unethical behavior
with the promotion of research include decreasing the
length of research proposals and informed consent forms,
and giving different review processes according to the risk
of the intervention and the benefits to patients.
Clinical trial reporting has also been constantly develop-
ing to increase transparency in clinical research. One
example is the database registry clinicaltrials.gov,5 which
has had a significant impact on clinical research. This is also
the case for the Consolidated Standards of Reporting Trials
(CONSORT),6 an important effort to improve transparency
in reporting randomized controlled trials so that readers can
better understand a study’s design, methodology and the
validity of its results.7
Globalization is also having important effects on the
conduct of clinical research. Brunoni and Fregni1 found that
more multicenter trials are being conducted. Glickman
et al.,8 who discuss the economic benefits of globalization,
found that clinical trials increasingly occur on a global scale
and claim that one-third of trials are now being conducted
in developing countries,9 as pharmaceutical and medical
device companies have embraced globalization.8 This
clearly raises numerous ethical concerns, including the
testing of drugs for wealthy populations in human subjects
of developing countries, the exacerbation of economic
disparities and exploitation of low-income workers in
developing countries, and their exposure to potentially
dangerous drugs that could not be approved for testing in
developed countries.
With this rapidly changing environment and increasingly
complex system, the training of clinical researchers becomes
ever more critical. One of the topics in clinical research that
needs to be addressed is the increasing number of studies
that use complex statistical analyses which can be difficult
for readers to interpret.10 Standard clinical research training
requires students to be present on site, but this prevents
some from participating owing to limited time and funds.
One of the more innovative models of training programs for
clinical researchers uses the principle of collaborative
learning,11 in which participants build and learn by
discussing the concepts and ethics of clinical research in a
course forum that blends live lectures (via video-conference)
with online discussion and small-group work with highly
trained teaching assistants.
One final issue is that with the increasing complexity of
biomedical research, translational research has also become
more complex. The immediate consequence is that dis-
coveries at the laboratory bench may not be translated into
full clinical trials to validate them.12 The U.S. National
Institutes of Health (NIH) is aware of this problem and has
created ‘‘the Clinical and Translational Science Awards
(CTSA) Consortium’’ to link institutions in an attempt to
catalyze translational research.13 However, researchers need
to be engaged in order for the program to succeed.
In conclusion, the often painful lessons from the past have
made clinical trials safer and contributed to development of
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novel treatments. However, in the era of globalization, new
ethical challenges arise as does the need for training programs
to promote the development of discoveries in medicine.
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